Idera Pharmaceuticals Announces Tilsotolimod Program Updates to be Presented at AACR Virtual Annual Meeting 2020
April 23, 2020 07:30 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., April 23, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera”) (Nasdaq: IDRA) today announced that updates on ILLUMINATE-206 and ILLUMINATE-101, two studies investigating...
TAOP Raises $2 Million from Recent Financing
March 30, 2020 08:00 ET
|
Taoping Inc.
SHENZHEN, China, March 30, 2020 (GLOBE NEWSWIRE) -- Taoping Inc. (NASDAQ: TAOP, the “Company”), a leading provider of internet-based smart display screens, and a new-media ecosystem that enables...
Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
March 12, 2020 07:30 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., March 12, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ: IDRA) reported on March 11, 2020 its financial and operational results for the fourth quarter and year...
Idera Pharmaceuticals Completes Enrollment in ILLUMINATE-301, its Registrational Trial of Tilsotolimod in Combination with Ipilimumab in Patients with Anti-PD-1 Refractory Advanced Melanoma
March 05, 2020 07:00 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., March 05, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or “the company”) (NASDAQ: IDRA) today announced completion of patient enrollment into ILLUMINATE-301, its...
Amunix Pharmaceuticals Announces the Appointment of Dr. Maninder Hora as Chief Technical Operations Officer
August 27, 2019 07:03 ET
|
Amunix Pharmaceuticals, Inc.
MOUNTAIN VIEW, Calif., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Amunix Pharmaceuticals, Inc. (“Amunix”), a biopharmaceutical company focused on enabling the promise of potent immune-activating...
Amunix Pharmaceuticals Announces the Appointment of Dr. Bryan Irving as Chief Scientific Officer
June 26, 2019 07:05 ET
|
Amunix Pharmaceuticals, Inc.
MOUNTAIN VIEW, Calif., June 26, 2019 (GLOBE NEWSWIRE) -- Amunix Pharmaceuticals, Inc. (“Amunix”), a biopharmaceutical company focused on enabling the promise of potent immune-activating...
Combination of first-in-class NBTXR3, radiotherapy, and anti-PD-1 immunotherapy demonstrate efficacy in treating resistant pre-clinical in vivo models of lung cancer
April 02, 2019 12:56 ET
|
NANOBIOTIX
Data presented at AACR Annual Meeting 2019 In vivo study conducted alone or in collaboration with The University of Texas MD Anderson Cancer Center demonstrated: NBTXR3 in combination with a PD-1...
Efficacité de la combinaison NBTXR3 (premier produit de sa classe), radiothérapie et immunothérapie avec anti-PD-1 démontrée dans le cancer du Poumon résistant dans des modèles précliniques in vivo
April 02, 2019 12:56 ET
|
NANOBIOTIX
Efficacité de la combinaison NBTXR3 (premier produit de sa classe), radiothérapie et immunothérapie avec anti-PD-1 démontrée dans le cancer du Poumon résistant dans des modèles précliniques in vivo ...
Allant Group Boosts Big Data Analytics With 16X Performance Improvement Using Kaminario K2
July 17, 2013 11:00 ET
|
Kaminario
NEWTON, MA--(Marketwired - Jul 17, 2013) - Kaminario, the leading scale-out all-flash array provider, today announced that Allant Group, a leading marketing and audience management platform, has...
Conatus Capital Management Increases Storage Performance by 600 Percent Using Kaminario K2 in Its Virtualized Environment
July 11, 2013 11:00 ET
|
Kaminario
NEWTON, MA--(Marketwired - Jul 11, 2013) - Kaminario, the leading scale-out all-flash array provider, today announced that Conatus Capital Management LP ("Conatus"), a Connecticut-based investment...